Argos Therapeutics (ARGS) Reports Q3 Loss of $0.10/Share

Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.10), versus ($0.32) reported last year. Revenue for the quarter came in at $53.5 thousand, versus $146.76 thousand reported last year.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Faraday Future signs robotics distributor deal, plans partner event
• Beike (BEKE) PT Raised to $23 at Morgan Stanley